A significant proportion of strokes in patients with atrial fibrillation are noncardioembolic, suggesting that stroke subtyping should be incorporated into risk stratification to optimize antithrombotic therapy.
Answers are grounded in this paper and cite their sources.
May support stroke subtyping in AF risk models; leaves open impact on antithrombotic selection.
-Vasc score), antithrombotic agents may exert differential effects depending on stroke etiology and stroke subtyping should be evaluated as an additional component of risk stratification that could facilitate optimal management. In the present study, we summarize the evidence on noncardioembolic (non-CE) stroke and treatment approaches based on different stroke subtypes in patients with AF. In particular, approximately one-third of patients with AF seem to suffer a non-CE stroke. Within this category, 11% to 24% of patients present high-grade carotid stenosis and 9% to 16% of ischemic strokes are classified as lacunar. In terms of secondary prevention, the effectiveness of OACs in preventing non-CE stroke has been disputed. Additional large-scale prospective studies are warranted to assess the pathophysiologic stroke mechanisms in patients with AF and compare the differential efficacy of antithrombotic treatment strategies in non-CE ischemic syndromes.
No takes yet. Share an insight, caveat, or question.
Katsi et al. (2018) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: